Biotechnology News and Research

RSS

Mathematical model predicts progress of tumors from early stages to metastasis

Researchers from the University of Miami (UM) and the University of Heidelberg in Germany have developed a mathematical model to understand and predict the progress of a tumor, from its early stages to metastasis, in hopes of creating highly personalized treatment strategies for patients who have cancer. The findings are published in Nature's new online journal Scientific Reports.

1 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Affymetrix to commercialize four Axiom genotyping arrays for the major populations

Affymetrix, Inc. today announced plans to commercialize four Axiom population-optimized arrays used to analyze 100,000 samples collected from volunteers in one of the nation's largest and most diverse genomics projects funded by the National Institutes of Health.

1 Aug 2011

Researchers identify new plasma membrane sculpting protein

The research group of Professor Pekka Lappalainen at the Institute of Biotechnology, University of Helsinki, has identified a previously unknown mechanism which modifies the structure of plasma membranes in intestinal epithelial cells.

1 Aug 2011

New device can produce blood-based diagnostic results in minutes

Samuel K. Sia, assistant professor of biomedical engineering at Columbia Engineering, has developed an innovative strategy for an integrated microfluidic-based diagnostic device-in effect, a lab-on-a-chip-that can perform complex laboratory assays, and do so with such simplicity that these tests can be carried out in the most remote regions of the world.

1 Aug 2011

Human genes can be patented in U.S. - Court overrules previous ruling

A lower court in the U.S. had earlier ruled that human genes cannot be patented by biotech companies who use them for diagnostic purposes. Now a federal appeals court ruled on Friday that genes can be patented. The Court of Appeals for the Federal Circuit, which specializes in patent cases, said that Myriad Genetics was entitled to patents on two human genes used to predict if women have an increased risk of getting breast and ovarian cancer.

31 Jul 2011

FDA should collect information needed to develop new framework for 510(k) clearance process

The U.S. Food and Drug Administration should gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices, says a new report from the Institute of Medicine.

30 Jul 2011

EMBL-EBI receives contract to lead UKPMC online resource for life science researchers

The European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) has been awarded the contract to run and lead the development of UK PubMed Central (UKPMC), the free online literature resource for life science researchers.

30 Jul 2011

CDC, ZKBS classifies Advaxis Agents as non-pathogenic materials

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has received affirmation by the Public Health Service of the U. S. Centers for Disease Control and Prevention and the Zentrale Kommission für die Biologische Sicherheit, the Central Commission for Biological Safety in Germany, that Advaxis strains, constructs and immunotherapies have been attenuated to the point that they are classified as non-pathogenic materials for handling and shipment.

30 Jul 2011

Therapeutic hypothermia might not be effective for children after heart attack

Intravenous delivery of cold fluids to reduce body temperature quickly after a heart attack and improve neurologic outcomes may not be as effective in children as it is in adults, according to a study reported in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal published by Mary Ann Liebert, Inc.

30 Jul 2011

Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies

Baxter International Inc. announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.

From Baxter International Inc. 30 Jul 2011

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.

30 Jul 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome.

29 Jul 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

Solazyme launches anti-aging skincare line, Algenist at Space NK stores

Solazyme, Inc., a renewable oil and bioproducts company, has signed a distribution agreement with the United Kingdom's most innovative beauty retailer, Space NK, to expand the sales network of the company's luxury skincare line, Algenist, to include all 60 Space NK stores throughout the country.

28 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

Reprogrammed kidney cells could make transplants and dialysis things of the past

Approximately 60 million people across the globe have chronic kidney disease (CKD), and many will need dialysis or a transplant. Breakthrough research published in the Journal of the American Society Nephrology indicates that patients' own kidney cells can be gathered and reprogrammed.

28 Jul 2011

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

28 Jul 2011

Biotechnology News and Research

Mathematical model predicts progress of tumors from early stages to metastasis

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

Affymetrix to commercialize four Axiom genotyping arrays for the major populations

Researchers identify new plasma membrane sculpting protein

New device can produce blood-based diagnostic results in minutes

Human genes can be patented in U.S. - Court overrules previous ruling

FDA should collect information needed to develop new framework for 510(k) clearance process

EMBL-EBI receives contract to lead UKPMC online resource for life science researchers

CDC, ZKBS classifies Advaxis Agents as non-pathogenic materials

Therapeutic hypothermia might not be effective for children after heart attack

Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

Amgen reports 8% increase in second quarter total product sales to $3,893 million

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Solazyme launches anti-aging skincare line, Algenist at Space NK stores

POZEN reports revenue of $4.6 million for second quarter 2011

Reprogrammed kidney cells could make transplants and dialysis things of the past

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News